ERFA THYROID TABLET

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

THYROID

Доступна с:

ERFA CANADA 2012 INC

код АТС:

H03AA05

ИНН (Международная Имя):

THYROID GLAND PREPARATIONS

дозировка:

60MG

Фармацевтическая форма:

TABLET

состав:

THYROID 60MG

Администрация маршрут:

ORAL

Штук в упаковке:

100

Тип рецепта:

Prescription

Терапевтические области:

THYROID AGENTS

Обзор продуктов:

Active ingredient group (AIG) number: 0107351001; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2020-05-20

Характеристики продукта

1
PRESCRIBING INFORMATION
Pr
ERFA THYROID
Desiccated Thyroid C.S.D.
30, 60, 125 mg Tablets
Hypothyroidism Therapy
Canada, H4P 2P5
Montréal, Quebec
8250 Décarie Blvd, suite 110
Submission control No.:
238182
Date
of
Revision:
19-May-2020
2
PRESCRIBING INFORMATION
PR
ERFA THYROID
DESICCATED THYROID
30, 60 AND 125 MG TABLETS
THERAPEUTIC CLASSIFICATION
HYPOTHYROIDISM THERAPY
ACTIONS AND CLINICAL PHARMACOLOGY
The principal pharmacologic effect of exogenous thyroid hormones is to
increase the metabolic
rate of body tissues.
The normal thyroid gland contains approximately 200 µg of
levothyroxine (T4)/g of gland, and 15
µg of triiodothyronine (T3)/g. The ratio of these two hormones in the
circulation does not
represent the ratio in the thyroid gland, since about 80% of
peripheral triiodothyronine comes
from monodeiodination of the outer ring of levothyroxine. Peripheral
monodeiodination of
levothyroxine at the 5 position (inner ring) also results in the
formation of reverse
triiodothyronine (r T3), which is calorigenically inactive. These
facts would seem to advocate
levothyroxine as the treatment of choice for the hypothyroid patient
and to mitigate against the
administration of hormone combinations which while normalizing
thyroxine levels, may produce
triiodothyronine levels in the thyrotoxic range.
Triiodothyronine (T3) level is low in the fetus and newborn, in old
age, in chronic caloric
deprivation, hepatic cirrhosis, renal failure, surgical stress, and
chronic illnesses representing
what has been called the “low triiodothyronine syndrome.”
Pharmacokinetics:
Animal studies have shown that T4 is only partially absorbed from the
gastrointestinal tract. The degree of absorption is dependent on the
vehicle used for its
administration and by the character of the intestinal contents, the
intestinal flora, including
plasma protein, soluble dietary factors, all of which bind thyroid and
thereby make it unavailable
for diffusion. Only 41% is absorbed when given in a gelatin capsule as
opposed to a 74 percent
absorpti